英國臨床營養市場 - 2025-2033

2024 年英國臨床營養市場規模達到 9.4093 億美元，預計到 2033 年將達到 10.6955 億美元，在 2025-2033 年預測期內的複合年成長率為 2.4%。

臨床營養產品是幫助患者維持健康的藥品。它透過提供足夠的補充劑（如礦物質、維生素等）來幫助改善代謝系統。臨床營養產品透過提供充足的補充劑（如礦物質、維生素和其他補充劑）有助於維持患者的健康並改善身體的代謝系統。

英國臨床營養市場是一個致力於為有特殊健康需求的患者，特別是患有慢性疾病或營養不良的患者提供專門的營養支持和產品的行業。該市場包括多種產品，如腸內和腸外營養解決方案、醫療食品和膳食補充劑，旨在滿足不同醫療保健環境中個人的營養需求。

臨床營養學可以定義為研究飲食、營養和健康結果之間關係的領域。它涵蓋與各種醫療狀況相關的營養問題的預防、診斷和管理。臨床營養的主要目標是確保患者獲得足夠的營養來支持他們的康復和整體健康，特別是在由於疾病或醫療而導致傳統飲食攝取不足的情況下。這些因素推動了英國臨床營養市場的擴張。

市場動態：

促進因素與約束因素

代謝紊亂盛行率上升

英國臨床營養市場由於代謝紊亂盛行率上升、醫療支出高以及新興經濟體中產階級崛起等因素而經歷成長，預示著市場正在不斷成長。

肥胖、高血壓、胰島素抗性、高血脂等代謝性疾病發生率上升是全球重大公共衛生問題。這些疾病與慢性退化性疾病有關，例如第 2 型糖尿病、肥胖症和心血管疾病。營養在代謝紊亂中的作用已得到充分研究，但人們對闡明營養素/食物對人體代謝和代謝紊亂的作用的興趣仍日益濃厚。

例如，根據國際糖尿病聯盟的數據，總共使用了來自 39 個國家的 60 個資料來源來估計該地區成年人的糖尿病發生率。資料顯示，2045年，歐洲地區的糖尿病盛行率（9.2%）和糖尿病患者數（6,100萬人）將增加13%。

因此，代謝紊亂和其他慢性疾病數量的增加將直接增加對臨床營養的需求，這將有助於市場在預測期內成長。此外，消費者對健康和保健的日益關注促進了英國臨床營養市場的擴張。

缺乏臨床營養意識

臨床營養的需求日益增加，但已開發國家和發展中國家都缺乏對醫療保健和飲食的認知。由於缺乏對維生素和營養的正確知識以及不正確的訊息，這種缺乏認知會導致缺陷和疾病。對健康和衛生的教育和直接支持是不夠的。儘管有活動提高人們對不同疾病的臨床營養益處的認知，但人們仍然缺乏對各種疾病的臨床營養的了解，這預計會阻礙市場的發展。

然而，缺乏認知（尤其是在新興國家）和嚴格的政府監管是導致替代營養方式採用率較低的一些限制因素。臨床營養市場的成長可能會受到影響在世界上最不已開發地區，由於拒絕合理的營養攝取方式和缺乏對新方法的接受，這些地區的生活水準相對較低。

公眾普遍缺乏對臨床營養在管理健康狀況方面的重要性的認知。許多人沒有認知到營養如何影響慢性疾病或有助於疾病的恢復。因此，上述因素可能會限制英國臨床營養市場的潛在成長。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

• 影響因素
  • 驅動程式
    • 代謝紊亂盛行率上升
  • 限制
    • 缺乏臨床營養意識
  • 機會
  • 影響分析

第5章：戰略洞察與產業展望

• 市場領導者和先驅者
  • 新興先鋒和傑出參與者
  • 擁有最大、最暢銷品牌的成熟領導者
  • 擁有成熟產品的市場領導者
• CXO 觀點
• 最新進展與突破
• 案例研究/正在進行的研究
• 監管和報銷情況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 波特五力分析
• 供應鏈分析
• 專利分析
• SWOT 分析
• 未滿足的需求和差距
• 市場進入和擴張的推薦策略
• 情境分析：最佳情況、基本情況和最壞情況預測
• 定價分析和價格動態
• 關鍵意見領袖

第 6 章：依產品類型

• 嬰兒營養
• 腸內營養
• 腸外營養

第7章：依年齡層

• 成人
• 兒科

第 8 章：按給藥途徑

• 口服
• 腸內
• 腸外

第9章：按應用

• 腫瘤學
• 代謝紊亂
• 胃腸道疾病
• 神經系統疾病
• 其他

第 10 章：按配銷通路

• 醫院藥房
• 零售藥局
• 網路藥局

第 11 章：競爭格局

• 競爭格局
• 市場定位/佔有率分析
• 併購分析

第 12 章：公司簡介

• Abbott Laboratories (Abbott Nutrition)
• 公司概況
• 產品組合
  • 產品描述
  • 產品關鍵績效指標 (KPI)
  • 歷史和預測產品銷售量
  • 產品銷售量
• 財務概覽
  • 公司收入
  • 地區收入佔有率
  • 收入預測
• 關鍵進展
  • 合併與收購
  • 關鍵產品開發活動
  • 監管部門批准等
• SWOT 分析
• Nestle Health Science
• Baxter International Inc
• B. Braun Melsungen AG
• Danone (Nutricia)
• BASF SE
• Perrigo Company PLC
• DSM-Firmenich AG
• AYMES International Ltd
• Nualtra

第 13 章：附錄

The U.K. clinical nutrition market reached US$ 940.93 million in 2024 and is expected to reach US$ 1,069.55 million by 2033, growing at a CAGR of 2.4 % during the forecast period 2025-2033.

Clinical nutrition products are pharmaceutical products that help keep a patient healthy. It helps to improve the metabolic system by providing adequate supplements such as minerals, vitamins, and others. Clinical nutrition products are useful in maintaining the patient's health and improving the body's metabolic system by providing adequate supplements, such as minerals, vitamins, and other supplements.

The clinical nutrition market in the UK is a sector dedicated to providing specialized nutritional support and products for patients with specific health needs, particularly those suffering from chronic diseases or malnutrition. This market includes a diverse range of products such as enteral and parenteral nutrition solutions, medical foods, and dietary supplements that are designed to meet the nutritional requirements of individuals in various healthcare settings.

Clinical nutrition can be defined as the field that examines the relationship between diet, nutrition, and health outcomes. It encompasses the prevention, diagnosis, and management of nutritional issues associated with various medical conditions. The primary goal of clinical nutrition is to ensure that patients receive adequate nutrients to support their recovery and overall health, especially in situations where traditional dietary intake is insufficient due to illness or medical treatment. These factors have driven the U.K. clinical nutrition market expansion.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Metabolic Disorders

The UK clinical nutrition market is experiencing growth due to factors such as rising metabolic disorders prevalence, high healthcare spending, and the rise of the middle class in emerging economies, indicating a growing market.

The rise in the prevalence of metabolic diseases, such as obesity, hypertension, insulin resistance, and hyperlipidemia, is a significant public health issue worldwide. These disorders are associated with chronic degenerative diseases, such as type 2 diabetes, obesity, and cardiovascular disease. The role of nutrition in metabolic disorders is well investigated, but there is still a growing interest in elucidating the nutrients/foods that execute their actions on human metabolism and metabolic disorders.

For instance, according to the International Diabetes Federation, a total of 60 data sources from 39 countries were used to generate diabetes estimates among adults in the region. According to the data, the diabetes prevalence (9.2%) and number of people with diabetes (61 million) in Europe region will increase 13 % by 2045. Europe region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.

Hence, the rise in the number of metabolic disorders and other chronic diseases will increase the demand for clinical nutrition directly which will help the market to grow during the forecast period. Moreover, the increasing focus of consumers on health and wellness contributes to the U.K. clinical nutrition market expansion.

Lack of Awareness for Clinical Nutrition

The demand for clinical nutrition is increasing, but there is a lack of awareness about healthcare and diet in both developed and developing countries. This lack of understanding leads to deficiencies and disorders due to a lack of proper knowledge of vitamins and nutrition, and incorrect information. Education and direct support for health and hygiene are not sufficient. Despite campaigns promoting awareness about clinical nutrition benefits for different diseases, there is still a lack of understanding about clinical nutrition for various illnesses, which is expected to hamper the market.

However, lack of awareness especially in emerging countries, and stringent government regulations are a few of the restraints that may result in lower adoption of alternate means of nutrition. The clinical nutrition market growth can be affected in the least developed regions of the world with comparatively lower standards of living attributed to the refusal of rationalized means to consume nutrition and, lack of acceptance of newer approaches.

There is a widespread lack of understanding among the general public regarding the significance of clinical nutrition in managing health conditions. Many people fail to recognize how nutrition can influence chronic diseases or aid in recovery from illnesses. Thus, the above factors could be limiting the U.K. clinical nutrition market's potential growth.

Segment Analysis

The U.K. clinical nutrition market is segmented based on Product Type, Age Group, route of administration, application, Distribution Channel, and region.

Product Type:

The enteral nutrition segment is expected to dominate the U.K. clinical nutrition market share

The enteral nutrition segment holds a major portion of the U.K. clinical nutrition market share and is expected to continue to hold a significant portion of the U.K. clinical nutrition market share during the forecast period. Enteral nutrition is an essential aspect of healthcare for individuals with a functioning digestive system who are unable to eat or drink. Nestle Health Science, a leader in the field, offers a wide range of enteral feeding products and solutions designed to support various life stages, from pediatrics to healthy aging.

If the gut is working normally to absorb food and nutrients, then Enteral Nutrition is the preferred way of delivering nutritional support. In some patients, enteral nutrition may have to be delivered into the gut through a tube, but in others, it may be possible for them to take this by mouth. This segment has seen substantial growth due to several factors, such as the rising elderly population, the growing incidence of chronic diseases, and a trend towards care being provided in home settings.

Furthermore, major players in the industry key initiatives and expansion of the industry that would propel this segment growth in the U.K. clinical nutrition market. For instance, in October 2022, Galen Medical Nutrition, a subsidiary of Galen Limited, launched TYR EASY Tablets in the UK, marking the first solid-dose protein substitute option for individuals over 8 years old with tyrosinemia. This provides patients with a greater variety of protein substitutes to better suit their individual needs.

Also, in May 2021, Willows Veterinary Centre expanded its clinical nutrition service by launching a specialist-led parenteral nutrition service. Willows is one of the few specialist centers in Europe with a board-certified specialist in clinical nutrition. This service provides intravenous nutrition, including protein, carbohydrates, and fat solutions, to patients when other feeding methods are not possible. These factors have solidified the segment's position in the U.K. clinical nutrition market.

Competitive Landscape

The major global players in the pollinosis market include Abbott Laboratories (Abbott Nutrition), Nestle Health Science, Baxter International Inc, B. Braun Melsungen AG, Danone (Nutricia), BASF SE, Perrigo Company PLC, DSM-Firmenich AG, AYMES International Ltd, and Nualtra among others.

Key developments

• In January 2023, Nutricia, a Danone-owned company, launched its first plant-based medical nutrition drink, Fortimel PlantBased Energy, to address the nutritional needs of individuals who are malnourished or at risk of malnutrition due to illness. This ready-to-drink oral nutritional supplement is made with high-quality plant protein from pea and soy sources, making it suitable for vegans, vegetarians, flexitarians, and those with cow's milk protein allergies. It is designed to match the nutritional profile of the original dairy formula.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The U.K. clinical nutrition market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Application
• 3.5. Snippet by Distribution Channel
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Metabolic Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness for Clinical Nutrition
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest largest-selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Infant Nutrition*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Enteral Nutrition
• 6.4. Parenteral Nutrition

7. By Age Group

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 7.1.2. Market Attractiveness Index, By Age Group
• 7.2. Adult*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pediatric

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Enteral
• 8.4. Parenteral

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Oncology*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Metabolic Disorders
• 9.4. Gastrointestinal Disorders
• 9.5. Neurological Disorders
• 9.6. Others

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Abbott Laboratories (Abbott Nutrition) *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Nestle Health Science
• 12.3. Baxter International Inc
• 12.4. B. Braun Melsungen AG
• 12.5. Danone (Nutricia)
• 12.6. BASF SE
• 12.7. Perrigo Company PLC
• 12.8. DSM-Firmenich AG
• 12.9. AYMES International Ltd
• 12.10. Nualtra

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us